Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
01/07/26	CN¥13.49	+6.98%	14,698,200
30/06/26	CN¥12.61	-1.87%	13,066,300
29/06/26	CN¥12.85	-2.95%	21,777,900
26/06/26	CN¥13.24	-5.36%	12,592,200
25/06/26	CN¥13.99	-4.96%	14,323,300

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 01/07/2026			5-day change	1st Jan Change
13.49 ^CNY	+6.98%		-8.36%	+15.30%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	5.46B 804M 706M 649M 605M 1.14B 76.4B 1.16B 7.81B 3.03B 37.5B 3.02B 2.95B 131B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	5.81B 855M 751M 691M 644M 1.21B 81.28B 1.24B 8.31B 3.22B 39.9B 3.21B 3.14B 139B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.74%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-24	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 30, 2026	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
10/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
22/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI

1 day	+6.98%
1 week	-8.36%
Current month	+6.98%
1 month	-18.29%
3 months	+18.96%
6 months	+15.30%
Current year	+15.30%

GuiZhou SanLi Pharmaceutical Co.,Ltd Share Price

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	12.1	14.32
1 month	12.1	17.23
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	26/05/2024
Hai Zhang CEO	Chief Executive Officer	41	31/08/2011
Ke Guo DFI	Director of Finance/CFO	39	31/10/2024

Director	Title	Age	Since
Hai Zhang CHM	Chairman	41	28/02/2018
Qian Fan Zhang BRD	Director/Board Member	41	28/02/2018
Yong Jian Sheng BRD	Director/Board Member	52	27/01/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
01/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
04/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	+6.98%	-8.36%	+14.91%	-20.93%	804M
ELI LILLY AND COMPANY	-0.64%	+6.67%	+53.59%	+154.11%	1,063B
JOHNSON & JOHNSON	+0.00%	+5.39%	+62.89%	+53.44%	611B
ABBVIE INC.	-0.23%	+6.88%	+32.14%	+86.34%	444B
ROCHE HOLDING AG	+1.61%	-0.96%	+26.12%	+20.22%	324B
ASTRAZENECA PLC	+1.79%	+0.18%	+35.59%	+35.80%	285B
NOVARTIS AG	+0.68%	-0.33%	+27.58%	+41.83%	283B
NOVO NORDISK A/S	-0.40%	+2.34%	-26.83%	-40.32%	219B
AMGEN INC.	-0.22%	+2.82%	+24.37%	+62.75%	195B
GILEAD SCIENCES, INC.	-0.29%	+0.65%	+12.75%	+63.45%	156B
Average	+1.09%	+2.19%	+26.31%	+45.67%	358.15B
Weighted average by Cap.	+0.47%	+4.15%	+38.25%	+77.26%

	2024	2025
Net sales	2.14B 316M 277M 255M 238M 448M 30.01B 457M 3.07B 1.19B 14.73B 1.19B 1.16B 51.26B	1.7B 251M 220M 203M 189M 356M 23.83B 363M 2.44B 944M 11.7B 941M 921M 40.71B
Net income	274M 40.33M 35.41M 32.59M 30.37M 57.28M 3.83B 58.45M 392M 152M 1.88B 151M 148M 6.55B	46.25M 6.81M 5.98M 5.5M 5.13M 9.67M 647M 9.87M 66.17M 25.64M 318M 25.56M 25.01M 1.11B
Net Debt	108M 15.85M 13.91M 12.81M 11.93M 22.51M 1.51B 22.96M 154M 59.68M 740M 59.5M 58.21M 2.57B	349M 51.32M 45.06M 41.48M 38.65M 72.89M 4.88B 74.37M 499M 193M 2.4B 193M 189M 8.34B